A Hemodialysis Catheter Designed to be Different from Day 1

The Pristine™ Long-Term Hemodialysis Catheter is designed
to be different from initial placement.

Meet the Pristine™ Long-Term Hemodialysis Catheter

  • The Pristine™ Long-Term Hemodialysis Catheter is designed to support anterior, posterior tip placement orientation in the mid right atrium
  • The notched tip of the Pristine™ Catheter is designed to help resist positional occlusion
  • As a leading innovator in the ESKD space, BD is focused on expanding options for physicians and their patients. Learn more about the latest tip design to join the BD long-term hemodialysis portfolio.

The Pristine™ Catheter’s unique Y-Tip™
Distal Lumen Design offers innovation

  • Side-hole free tip is designed to help facilitate blood clot aspiration prior to hemodialysis treatment
  • Side-hole free tip designed to help minimize thrombus adhesion that can be associated with side-hole catheters
  • Demonstrated low recirculation rates in both forward and reverse¹

Sign up here to learn more about BD’s latest long-term hemodialysis innovation

Fill out this form to connect with a local representative in your area and get more information about the Pristine™ Long-Term Hemodialysis Catheter and benefits it can bring to your practice.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Day, Month date, time

Name
Title

Name
Title

Name
Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Day, Month date, time

Name
Title

Name
Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CTA

Video title here

Play

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

Heading

Placeholder

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Intervention-Free at 60 Days

interimg

Primary patency was defined as a catheter that provided adequate hemodialysis (flow >300ml/min) without the need for additional interventions (i.e., TPA infusions or fibrin sheath stripping or catheter exchange) to maintain flow or correct device failure.

In a prospective, single-center, non-randomized, open-label feasibility study performed in the Dominican Republic, 45 patients who received the 15.5F Pristine™ Long-Term Hemodialysis Catheter were followed for 6 months post-catheter implantation. All catheters were patent at 30 days post implantation. Primary patency at 60- and 180-days post procedure was 100% and 91%, respectively. This was a prospective analysis without prespecified, hypothesis-tested endpoints. Data are descriptive only. The study was conducted on subjects with End Stage Renal Disease or Acute Renal Failure outside of the United States where clinical practices may differ and results may or may not be representative of patients in the United States.²

REFERENCES

1. Tested using 55 cm tip-to-cuff length Pristine™ Long-Term Hemodialysis Catheters (n=37). Recirculation test performed using 5% saline as blood simulant at a blood flow rate of ~5 liters/minute and catheter flow rate of 350 mL/min. The mean recirculation rates were 2.7% in forward flow and 2.8% in reverse flow. Bench data on file, Becton, Dickinson and Company, Tempe, AZ. Bench data may not necessarily correlate to clinical performance. Different test methods may yield different results. 

2. Data on file. Becton, Dickinson and Company, Tempe, AZ


The Pristine™ Long-Term Hemodialysis Catheters are indicated for use in attaining short-term or long-term vascular access for hemodialysis, apheresis, and infusion. Access is attained via the internal jugular vein, subclavian vein, or femoral vein. Catheters longer than 40 cm are intended for femoral vein insertion. Catheters may be inserted percutaneously. Pristineᵀᴹ Catheters are contraindicated for: Thrombosed vessels · Confirmed infection, bacteremia or septicemia · Inadequate anatomy for placement of the device · Known or suspected sensitivity to the device materials · Prior or unresolved venous thrombosis at the proposed placement site. Potential complications may include air embolism, catheter thrombosis, and infection. See Instructions For Use for the complete list of potential complications. Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions. BD, the BD Logo, Pristine, and Y-Tip are trademarks of Becton, Dickinson and Company or its affiliate. © 2021 BD. All Rights Reserved. Illustrations by Mike Austin. Copyright © 2021 BD-35497.